A Randomized Open Label Study Comparing the Efficacy, Safety, and Tolerability of Oral Administration of Amantadine and Ribavirin With Oseltamivir Versus Oseltamivir to Influenza A Virus Infected Immunocompromised Subjects

This Phase 2, open label, randomized study will investigate the virologic benefit, clinical efficacy, safety, and tolerability of amantadine and ribavirin with oseltamivir (TCAD) versus oseltamivir monotherapy for the treatment of all strains of influenza A in immunocompromised adult and pediatric subjects.

Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.

Investigator(s):

Intervention(s):

  • drug : ADS-8902
  • drug : Oseltamivir Phosphate

Phase: Phase 2

Eligibility

Ages Eligible For Study:

1 Year - 65 Years

Inclusion Criteria

- Confirmed influenza A by rapid antigen testing - Immunocompromised as defined by recent solid organ or hematopoietic transplant, chronic graft vs. host disease, taking at least 2 immunosuppressants, undergoing chemotherapy, taking high dose chemotherapeutics, HIV positive - Clinical diagnosis of influenza - Onset of illness within 5 days - Male and female subjects agree to contraception through 24 weeks after last dose

External Links

Explore related trials

Contact information

Primary Contact:

Joanna Schaenman 6503870127

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: